膜杰作
Star Staining
优势与特点（FAB）
- Cost effective - Sufficient quantity at a lower price, accounting for dilution and pipetting losses.
- Comprehensive validation - Validated with various antibody subtypes and antibody drugs.
- Simple and fast operation - No complicated washing steps, significantly reducing time.
- High batch consistency - Strict control over raw materials and finished product quality, ensuring a stable supply.
- Accurate and reliable results - High sensitivity with minimal matrix effects.
- High throughput capability - Supports 500 tests, ideal for high-throughput screening.
- Fast completion - Results in just 1 hour.
产品参数（Product Specifications）
| Assay Type | Inhibition-TR-FRET |
| Analyte | Anti-TL1A Neutralizing Antibody |
| Format | 100T/500T |
| Reactivity | Human |
| Regulatory Status | RUO |
| Sensitivity | IC50=2.816nM |
| Standard Curve Range | 0.1302 nM-66.6667 nM |
| Assay Time | 1 hr |
| Suitable Sample Type | For screening assay of neutralizing antibodies binding to the human TL1A |
| Sample volume | 10 μL |
产品概述（Product Overview）
The Human TL1A-DR3 inhibition Kit (TR-FRET) is based on a homogeneous (no wash) competition TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer) to screening for inhibitors of human TL1A binding to human DR3 within 0.5-1 hours. It can also be used as a universal detection tool to identify the ability of TL1A to bind to human DR3.
存储（Storage）
组分（Materials Provided）
| ID | Components | Size |
| FRT02-C01 | Human TL1A Protein Europium-chelate | 100 tests/500 tests |
| FRT02-C02 | FA Labeled Human DR3 Protein | 100 tests/500 tests |
| FRT02-C03 | Monoclonal Anti-TL1A Antibody, Human IgG1 | 20 μg/100 tests
100 μg/500 tests |
| FRT02-C04 | Sample Dilution Buffer | 10 mL/100tests & 500tests |
| FRT02-C05 | Detection Buffer | 10 mL/100tests & 500tests |
原理（Assay Principles）
This Human TL1A-DR3 inhibition kit (TR-FRET) is based on TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer). Use a mixture of biotinylated human TL1A and Europium-chelate labeled streptavidin as the donor and FA labeled human DR3 protein as the acceptor.
- In the absence of inhibitors for human TL1A binding to human DR3, the donor and acceptor are in close proximity due to the binding of human TL1A and FA-labeled human DR3. Upon excitation with a specific light source, the donor emits a 620 nm signal, which is absorbed by the acceptor, resulting in a 665 nm emission.
- In the presence of inhibitors that block the binding of human TL1A to human DR3, the donor-acceptor interaction is disrupted, preventing FRET from occurring.
活性（Bioactivity）-TR-FRET Please refer to DS document for the assay protocol.
Inhibition of Europium-chelate labeled human TL1A: FA labeled human DR3 binding by Human Anti-TL1A Neutralizing Antibody
Premix serial dilutions of Human Anti-TL1A Neutralizing Antibody (1:2 serial dilution, from 10 μg/mL to 0.01953125 μg/mL (66.6667-0.1302 nM)) and Human TL1A Protein Europium-chelate and incubate at room temperature (20℃-25℃) for 0.5 hours. Then add FA Labeled Human DR3 Protein and incubate at room temperature (20℃-25℃) for 0.5 hours. Detection was performed with IC50 of 2.816nM. The assay was performed according to the above-described Datasheet (QC tested).
背景（Background）：TL1A-DR3
The TL1A protein, belongs to the tumor necrosis factor (TNF) family and is a receptor for TNFRSF25 and TNFRSF6B. TL1A is involved in the activation of NF-κB and C-Jun pathways, which can be used as a regulator of mucosal immunity and participate in the immune pathway of inflammatory bowel disease (IBD) pathogenesis.
